Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Stanford University
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital